Search

Your search keyword '"Sternik, Leonid"' showing total 525 results
Start Over Author "Sternik, Leonid"
525 results on '"Sternik, Leonid"'

22. Extracorporeal membrane oxygenation in obstetric patients: An Israeli nationwide study.

Author

Yahav‐Shafir, Dana, Ilgiyaev, Eduard, Galante, Ori, Gorfil, Dan, Statlender, Liran, Soroksky, Arie, Carmi, Uri, Sinai, Yitzhak Brzezinski, Iprach, Nisim, Haviv‐Yadid, Yael, Makhoul, Maged, Fatnic, Elena, Ginosar, Yehuda, Einav, Sharon, Helviz, Yigal, Fink, Daniel, Sternik, Leonid, and Kogan, Alexander

Subjects
EXTRACORPOREAL membrane oxygenation, COVID-19, PERINATAL period, PULMONARY hypertension, CRITICAL care medicine, AMNIOTIC fluid embolism, ARACHNOID cysts
Abstract

Background: The leading causes of maternal mortality include respiratory failure, cardiovascular events, infections, and hemorrhages. The use of extracorporeal membrane oxygenation (ECMO) as rescue therapy in the peripartum period for cardiopulmonary failure is expanding in critical care medicine. Methods: This retrospective observational study was conducted on a nationwide cohort in Israel. During the 3‐year period, between September 1, 2019, and August 31, 2022, all women in the peripartum period who had been supported by ECMO for respiratory or circulatory failure at 10 large Israeli hospitals were identified. Indications for ECMO, maternal and neonatal outcomes, details of ECMO support, and complications were collected. Results: During the 3‐year study period, in Israel, there were 540 234 live births, and 28 obstetric patients were supported by ECMO, with an incidence of 5.2 cases per 100 000 or 1 case per 19 000 births (when excluding patients with COVID‐19, the incidence will be 2.5 cases per 100 000 births). Of these, 25 were during the postpartum period, of which 16 (64%) were connected in the PPD1, and 3 were during pregnancy. Eighteen patients (64.3%) were supported by V‐V ECMO, 9 (32.1%) by V‐A ECMO, and one (3.6%) by a VV‐A configuration. Hypoxic respiratory failure (ARDS) was the most common indication for ECMO, observed in 21 patients (75%). COVID‐19 was the cause of ARDS in 15 (53.7%) patients. The indications for the V‐A configuration were cardiomyopathy (3 patients), amniotic fluid embolism (2 patients), sepsis, and pulmonary hypertension. The maternal and fetal survival rates were 89.3% (n = 25) and 100% (n = 28). The average ECMO duration was 17.6 ± 18.6 days and the ICU stay was 29.8 ± 23.8 days. Major bleeding complications requiring surgical intervention were observed in one patient. Conclusions: The incidence of using ECMO in the peripartum period is low. The maternal and neonatal survival rates in patients treated with ECMO are high. These results show that ECMO remains an important treatment option for obstetric patients with respiratory and/or cardiopulmonary failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Surgical ablation for atrial fibrillation: impact of diabetes mellitus

Author

Kogan, Alexander, primary, Grupper, Avishay, additional, Sabbag, Avi, additional, Ram, Eilon, additional, Jamal, Tamer, additional, Nof, Eyal, additional, Fisman, Enrique (Zvi), additional, Levin, Shany, additional, Beinart, Roy, additional, Frogel, Jonathan, additional, Raanani, Ehud, additional, and Sternik, Leonid, additional

Published
2023
Full Text
View/download PDF

39. Outcomes of Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 Patients: A Multi-Institutional Analysis

Author

Makhoul, Maged, primary, Keizman, Eitan, additional, Carmi, Uri, additional, Galante, Ori, additional, Ilgiyaev, Eduard, additional, Matan, Moshe, additional, Słomka, Artur, additional, Sviri, Sigal, additional, Eden, Arieh, additional, Soroksky, Arie, additional, Fink, Danny, additional, Sternik, Leonid, additional, Bolotin, Gil, additional, Lorusso, Roberto, additional, and Kassif, Yigal, additional

Published
2023
Full Text
View/download PDF

46. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant

Author

Peled, Yael, primary, Afek, Arnon, additional, Kreiss, Yitshak, additional, Rahav, Galia, additional, Nemet, Ital, additional, Kliker, Limor, additional, Indenbaum, Victoria, additional, Ram, Eilon, additional, Lavee, Jacob, additional, Segev, Amit, additional, Matezki, Shlomi, additional, Sternik, Leonid, additional, Raanani, Ehud, additional, Lustig, Yaniv, additional, Patel, Jignesh K., additional, and Mandelboim, Michal, additional

Published
2022
Full Text
View/download PDF

49. Timing of Lung Transplant Referral in Patients with Severe COVID-19 Lung Injury Supported by ECMO.

Author

Levy, Liran, Deri, Ofir, Huszti, Ella, Nachum, Eyal, Ledot, Stephane, Shimoni, Nir, Saute, Milton, Sternik, Leonid, Kremer, Ran, Kassif, Yigal, Zeitlin, Nona, Frogel, Jonathan, Lambrikov, Ilya, Matskovski, Ilia, Chatterji, Sumit, Seluk, Lior, Furie, Nadav, Shafran, Inbal, Mass, Ronen, and Onn, Amir

Subjects
COVID-19, LUNG transplantation, ETIOLOGY of diseases, MEDICAL referrals, EXTRACORPOREAL membrane oxygenation
Abstract

Severe respiratory failure caused by COVID-19 often requires mechanical ventilation, including extracorporeal membrane oxygenation (ECMO). In rare cases, lung transplantation (LTx) may be considered as a last resort. However, uncertainties remain about patient selection and optimal timing for referral and listing. This retrospective study analyzed patients with severe COVID-19 who were supported by veno-venous ECMO and listed for LTx between July 2020 and June 2022. Out of the 20 patients in the study population, four who underwent LTx were excluded. The clinical characteristics of the remaining 16 patients were compared, including nine who recovered and seven who died while awaiting LTx. The median duration from hospitalization to listing was 85.5 days, and the median duration on the waitlist was 25.5 days. Younger age was significantly associated with a higher likelihood of recovery without LTx after a median of 59 days on ECMO, compared to those who died at a median of 99 days. In patients with severe COVID-19-induced lung damage supported by ECMO, referral to LTx should be delayed for 8–10 weeks after ECMO initiation, particularly for younger patients who have a higher probability of spontaneous recovery and may not require LTx. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results